Sensai Cellular Performance

Sensai Cellular Performance Manufacturers

• Kanebo Cosmetics Inc.
  

  ×

  Sensai Cellular Performance | Mckesson

  

  ---

  • for maximum effectiveness, never dilute or drink fluids of any kind immediately before or after taking this product • adults and children 12 years of age and over: one or two tablespoons • children 2 to under 12: one or two teaspoons • repeat dose every 15 minutes or until distress subsides • do not take more than 5 doses in 1 hour without consulting a doctor

  Close
  No Recall

  More Info
• Kanebo Cosmetics Inc.
  

  ×

  Sensai Cellular Performance | Tya Pharmaceuticals

  

  ---

  2.1 Schizophrenia

  Dose Selection

  GEODON Capsules should be administered at an initial daily dose of 20 mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80 mg twice daily. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. In order to ensure use of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment.

  Efficacy in schizophrenia was demonstrated in a dose range of 20 mg to 100 mg twice daily in short-term, placebo-controlled clinical trials. There were trends toward dose response within the range of 20 mg to 80 mg twice daily, but results were not consistent. An increase to a dose greater than 80 mg twice daily is not generally recommended. The safety of doses above 100 mg twice daily has not been systematically evaluated in clinical trials [ ]. see Clinical Studies (14.1)

  Maintenance Treatment

  While there is no body of evidence available to answer the question of how long a patient treated with ziprasidone should remain on it, a maintenance study in patients who had been symptomatically stable and then randomized to continue ziprasidone or switch to placebo demonstrated a delay in time to relapse for patients receiving Geodon [ ]. No additional benefit was demonstrated for doses above 20 mg twice daily. Patients should be periodically reassessed to determine the need for maintenance treatment. see Clinical Studies (14.1)

  2.2 Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate)

  Acute Treatment of Manic or Mixed Episodes

  Dose Selection--Oral ziprasidone should be administered at an initial daily dose of 40 mg twice daily with food. The dose may then be increased to 60 mg or 80 mg twice daily on the second day of treatment and subsequently adjusted on the basis of tolerance and efficacy within the range 40 mg–80 mg twice daily. In the flexible-dose clinical trials, the mean daily dose administered was approximately 120 mg [ ]. see Clinical Studies (14.2)

  Maintenance Treatment (as an adjunct to lithium or valproate)

  Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40 mg–80 mg twice daily with food. Patients should be periodically reassessed to determine the need for maintenance treatment [ ] see Clinical Studies (14.2).

  2.3 Acute Treatment of Agitation in Schizophrenia

  Intramuscular Dosing

  The recommended dose is 10 mg to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day. Intramuscular administration of ziprasidone for more than three consecutive days has not been studied.

  If long-term therapy is indicated, oral ziprasidone hydrochloride capsules should replace the intramuscular administration as soon as possible.

  Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.

  Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.

  Intramuscular Preparation for Administration

  GEODON for Injection (ziprasidone mesylate) should only be administered by intramuscular injection and should not be administered intravenously. Single-dose vials require reconstitution prior to administration.

  Add 1.2 mL of Sterile Water for Injection to the vial and shake vigorously until all the drug is dissolved. Each mL of reconstituted solution contains 20 mg ziprasidone. To administer a 10 mg dose, draw up 0.5 mL of the reconstituted solution. To administer a 20 mg dose, draw up 1.0 mL of the reconstituted solution. Any unused portion should be discarded. Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final solution. This medicinal product must not be mixed with other medicinal products or solvents other than Sterile Water for Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  2.4 Dosing in Special Populations

  Dosage adjustments are generally not required on the basis of age, gender, race, or renal or hepatic impairment. Geodon is not approved for use in children or adolescents. Oral:

  Ziprasidone intramuscular has not been systematically evaluated in elderly patients or in patients with hepatic or renal impairment. As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with impaired renal function. Dosing adjustments are not required on the basis of gender or race [ ]. Intramuscular:see Use in Specific Populations (8)

  Close
  No Recall

  More Info
• Kanebo Cosmetics Inc.
  

  ×

  Sensai Cellular Performance | Pharmacia And Upjohn Company

  

  ---

  If diarrhea occurs during therapy, this antibiotic should be discontinued (see WARNING box).

  Clindamycin phosphate IM administration should be used undiluted.

  Clindamycin phosphate IV administration should be diluted (see Dilution for IV use and IV infusion rates below).

  Adults

  Parenteral (IM or IV Administration): Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides fragilis, Peptococcus species and Clostridium species other than Clostridium perfringens):

  600–1200 mg/day in 2, 3 or 4 equal doses.

  More severe infections, particularly those due to proven or suspected Bacteroides fragilis, Peptococcus species, or Clostridium species other than Clostridium perfringens:

  1200–2700 mg/day in 2, 3 or 4 equal doses.

  For more serious infections, these doses may have to be increased. In life-threatening situations due to either aerobes or anaerobes these doses may be increased. Doses of as much as 4800 mg daily have been given intravenously to adults (see Dilution for IV use and IV Infusion Rates section below).

  Single intramuscular injections of greater than 600 mg are not recommended.

  Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion as follows:

  To maintain serum clindamycin levels Rapid infusion rate Maintenance infusion rate Above 4 mcg/mL 10 mg/min for 30 min 0.75 mg/min Above 5 mcg/mL 15 mg/min for 30 min 1.00 mg/min Above 6 mcg/mL 20 mg/min for 30 min 1.25 mg/min Neonates (less than 1 month)

  15 to 20 mg/kg/day in 3 to 4 equal doses. The lower dosage may be adequate for small prematures.

  Pediatric patients 1 month of age to 16 years

  Parenteral (IM or IV) Administration: 20 to 40 mg/kg/day in 3 or 4 equal doses. The higher doses would be used for more severe infections. As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350 mg/m2/day for serious infections and 450 mg/m2/day for more severe infections.

  Parenteral therapy may be changed to oral CLEOCIN PEDIATRIC® Flavored Granules (clindamycin palmitate hydrochloride) or CLEOCIN HCl® Capsules (clindamycin hydrochloride) when the condition warrants and at the discretion of the physician.

  In cases of β-hemolytic streptococcal infections, treatment should be continued for at least 10 days.

  Dilution for IV use and IV Infusion Rates

  The concentration of clindamycin in diluent for infusion should not exceed 18 mg per mL. Infusion rates should not exceed 30 mg per minute. The usual infusion dilutions and rates are as follows:

  Dose Diluent Time 300 mg 50 mL 10 min 600 mg 50 mL 20 min 900 mg 50–100 mL 30 min 1200 mg   100 mL 40 min

  Administration of more than 1200 mg in a single 1-hour infusion is not recommended.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  Dilution and Compatibility

  Physical and biological compatibility studies monitored for 24 hours at room temperature have demonstrated no inactivation or incompatibility with the use of CLEOCIN PHOSPHATE Sterile Solution (clindamycin phosphate) in IV solutions containing sodium chloride, glucose, calcium or potassium, and solutions containing vitamin B complex in concentrations usually used clinically. No incompatibility has been demonstrated with the antibiotics cephalothin, kanamycin, gentamicin, penicillin or carbenicillin.

  The following drugs are physically incompatible with clindamycin phosphate: ampicillin sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and magnesium sulfate.

  The compatibility and duration of stability of drug admixtures will vary depending on concentration and other conditions. For current information regarding compatibilities of clindamycin phosphate under specific conditions, please contact the Medical and Drug Information Unit, Pharmacia & Upjohn Company (Division of Pfizer Inc).

  Physico-Chemical Stability of diluted solutions of CLEOCIN PHOSPHATE

  Room temperature: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles, demonstrated physical and chemical stability for at least 16 days at 25°C.

  Refrigeration: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles, demonstrated physical and chemical stability for at least 32 days at 4°C.

  IMPORTANT: This chemical stability information in no way indicates that it would be acceptable practice to use this product well after the preparation time. Good professional practice suggests that compounded admixtures should be administered as soon after preparation as is feasible.

  Close
  No Recall

  More Info
• Kanebo Cosmetics Inc.
  

  ×

  Sensai Cellular Performance | The Mentholatum Company

  

  ---

  • adults and children 12 years and over: apply patch to affected area as needed but not more than 4 times daily • children under 12 years: ask a doctor • for easy application; partially peel back protective film and apply exposed patch to site of pain. Carefully remove remaining film while pressing patch to skin.

  Close
  No Recall

  More Info
• Kanebo Cosmetics Inc.
  

  ×

  Sensai Cellular Performance | Product Quest Mfg

  

  ---

  Adults and children 12 years and over: apply patch to affected area as needed but not more than 4 times daily Children under 12 years: ask a doctor For easy application: grasy both ends of pad firmly, pull at both ends. Stretch pad until the backing separates. Remove protective film while applying pad directly to site of pain.

  Close
  No Recall

  More Info
• Kanebo Cosmetics Inc
  

  ×

  Sensai Cellular Performance | Kanebo Cosmetics Inc

  

  ---

  Apply sufficient quantity evenly before sun exposure.

  Re-apply frequently to maintain the original protection.

  Close
  No Recall

  More Info